Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Bauer

Showing results (371-380 of 408) with videos related to

Pageof 41
Sort By:
Nature Communications|March 9, 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationInga-Marie Schaefer, Yuexiang Wang, Cher-Wei Liang, et al.
JAMA Oncology|October 16, 2025
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus ReviewCésar Serrano, Sebastian Bauer, Jean-Yves Blay, et al.
Neurobiology of Disease|August 18, 2020
Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsyGary P Brennan, Sebastian Bauer, Tobias Engel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterMarcel Wiesweg, Saskia Ting, Henning Reis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2024
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorRainer Hamacher, Kim M Pabst, Phyllis F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Genetics|August 31, 2010
Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndromePeter M Krawitz, Michal R Schweiger, Christian Rödelsperger, et al.
Chemical Science|December 21, 2019
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797SJonas Lategahn, Marina Keul, Philip Klövekorn, et al.
Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.
Pageof 41

Showing results (371-380 of 408) with videos related to

Sort By:
Pageof 41
Nature Communications|March 9, 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationInga-Marie Schaefer, Yuexiang Wang, Cher-Wei Liang, et al.
JAMA Oncology|October 16, 2025
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus ReviewCésar Serrano, Sebastian Bauer, Jean-Yves Blay, et al.
Neurobiology of Disease|August 18, 2020
Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsyGary P Brennan, Sebastian Bauer, Tobias Engel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterMarcel Wiesweg, Saskia Ting, Henning Reis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2024
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorRainer Hamacher, Kim M Pabst, Phyllis F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Genetics|August 31, 2010
Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndromePeter M Krawitz, Michal R Schweiger, Christian Rödelsperger, et al.
Chemical Science|December 21, 2019
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797SJonas Lategahn, Marina Keul, Philip Klövekorn, et al.
Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.
Pageof 41